

---

## WilmerHale Advises Visterra in \$46.7M Series C Financing

OCTOBER 17, 2017

On October 5, 2017, Visterra, Inc., a clinical-stage biotechnology company that uses its novel Hierotope® platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines against such targets that are not adequately addressed with conventional approaches, announced that it has completed a Series C financing round raising a total of \$46.7 million, including a new extension totaling \$23.6 million.

The WilmerHale team representing Visterra in this transaction included [Lia Der Marderosian](#), [Molly Fox](#), [Emily Gainor](#) and [Sam Rothberg](#).

Visterra's press release is available at [www.visterrainc.com](http://www.visterrainc.com).